Abstract
BackgroundSwitching from intravenous (IV) to oral (PO) treatment as soon as patients are clinically stable can reduce the costs associated with IV administration.In this study, we selected levetiracetam, a drug...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: European Journal of Hospital Pharmacy: Science and Practice
Paper Title
Journal
Date
